Session » Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Date: Sunday, October 21, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 610

4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy

9:00AM-11:00AM: Abstract Number: 588

Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 590

Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years

9:00AM-11:00AM: Abstract Number: 576

An Analysis of Early Introduction of Adalimumab and Subsequent Bio-Free Condition in the Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 612

Anti-Drug Antibodies Detected By Competitive ELISA Can Predict Treatment Failure in Patients Taking Adalimumab

9:00AM-11:00AM: Abstract Number: 554

Are There Any Associations between ANA Development and Poor Treatment Response to Bdmards in RA Patients?

9:00AM-11:00AM: Abstract Number: 601

At Which Point and for Which Reasons Are Oral MTX Formulations Switched to Injectable Ones in RA Patients? Combined Results from 3 Independent Observational and Clinical Trials

9:00AM-11:00AM: Abstract Number: 546

Baricitinib: Early Vs. Delayed Start in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 582

Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib

9:00AM-11:00AM: Abstract Number: 550

Biologic Discontinuation in Rheumatoid Arthritis: A Population Based Study 1999-2017

9:00AM-11:00AM: Abstract Number: 618

Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 566

Capillary Blood Based Methotrexate Polyglutamate Assay for Monitoring Low Dose Methotrexate Therapy in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 568

Change in RF and Anti-CCP Isotype Levels in RA Patients Treated with Anti-TNF, Abatacept, Rituximab or Tocilizumab and Correlation with Clinical and Radiographic Outcomes: Data from a Randomized Trial

9:00AM-11:00AM: Abstract Number: 584

Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 579

Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients

9:00AM-11:00AM: Abstract Number: 553

Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings

9:00AM-11:00AM: Abstract Number: 597

Characteristics of Patients and Predictors of Composite Disease Activity Scores for Switching to Monotherapy Vs Continuing TNF Inhibitor and Methotrexate Combination Therapy in RA: A Retrospective Analysis of the Brigham and Women’s Rheumatoid Arthritis Sequential Study Registry

9:00AM-11:00AM: Abstract Number: 607

Clinical and Functional Response to Tofacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from the ORAL Strategy Trial

9:00AM-11:00AM: Abstract Number: 569

Clinical and Sociodemographic Characteristics of Patients with Rheumatoid Arthritis (RA) Starting Triple Therapy and a Combination of a TNF Inhibitor and Methotrexate from a Large US Registry

9:00AM-11:00AM: Abstract Number: 580

Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry

9:00AM-11:00AM: Abstract Number: 605

Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany

9:00AM-11:00AM: Abstract Number: 596

Combination of Intra-Articular Steroid Injection and Tofacitinib More Effective Than Tofacitinib in Rapid Radiographic Progression Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 604

Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis

9:00AM-11:00AM: Abstract Number: 572

Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®

9:00AM-11:00AM: Abstract Number: 581

Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX

9:00AM-11:00AM: Abstract Number: 599

Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)

9:00AM-11:00AM: Abstract Number: 547

Corticosteroid Bridging Strategies with Methotrexate Monotherapy in Early Rheumatoid and Undifferentiated Arthritis; A Comparison of Efficacy and Toxicity in 2 Clinical Trials

9:00AM-11:00AM: Abstract Number: 627

Corticosteroid Utilization before and after Initiation of Biologic Dmards between Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 589

DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 614

Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis

9:00AM-11:00AM: Abstract Number: 543

Disease Severity Among Bio-Naive RA Patients on Csdmards

9:00AM-11:00AM: Abstract Number: 622

DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study

9:00AM-11:00AM: Abstract Number: 544

Does Anti-Citrullinated Protein Antibody Status Modify Treatment Effect of Certain Biologic DMARDs?

9:00AM-11:00AM: Abstract Number: 552

Drug Tolerability and Discontinuation Reasons of 7 Biologics in 4466 Treatment Courses of Rheumatoid Arthritis -the Answer Cohort Study-

9:00AM-11:00AM: Abstract Number: 600

Early Versus Delayed Treatment in Patients with Rheumatoid Arthritis (RA) in Routine Care at a Single US Academic Center: Better Response According to MDHAQ (MultiDimensional Health Assessment questionnaire) for Patients Starting Treatment in the Initial 6 Months

9:00AM-11:00AM: Abstract Number: 624

Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 578

Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis

9:00AM-11:00AM: Abstract Number: 586

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort

9:00AM-11:00AM: Abstract Number: 563

Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study

9:00AM-11:00AM: Abstract Number: 620

Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 570

Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab

9:00AM-11:00AM: Abstract Number: 591

Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo

9:00AM-11:00AM: Abstract Number: 577

Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 565

Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 608

Half Dose Reduction of Methotrexate in Patient with RA Who Achieved Clinical Remission

9:00AM-11:00AM: Abstract Number: 545

How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry

9:00AM-11:00AM: Abstract Number: 583

Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 594

Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

9:00AM-11:00AM: Abstract Number: 560

Impact of Formulary Copayment Change on Treatment Patterns in Rheumatoid Arthritis Patients on Etanercept

9:00AM-11:00AM: Abstract Number: 592

Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 602

Individualised Infliximab Treatment: A Treatment Strategy Based on Therapeutic Drug Monitoring

9:00AM-11:00AM: Abstract Number: 611

Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort

9:00AM-11:00AM: Abstract Number: 613

Interim Analysis of Baseline Characteristics and Preferences of Administration Route of Rheumatoid Arthritis Patients Who Are Bio-Naïve or Switched between Advanced RA Treatments; A Multicenter, Prospective, Observational Study

9:00AM-11:00AM: Abstract Number: 551

Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 564

Levels of CXCL13 and sICAM1 Correlate with Disease Activity Score in Rheumatoid Arthritis (RA) Patients Treated with Tocilizumab (TCZ)

9:00AM-11:00AM: Abstract Number: 617

Long-Term Outcome of Rituximab in Rheumatoid Arthritis: Real World Experience

9:00AM-11:00AM: Abstract Number: 628

Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database

9:00AM-11:00AM: Abstract Number: 574

Longitudinal Efficacy Analysis of Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Dmards: Response Following Rescue from Baricitinib 2mg to 4mg Once-Daily

9:00AM-11:00AM: Abstract Number: 562

Low Inflammation on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis That Achieved Sustained Clinical Remission on Adalimumab

9:00AM-11:00AM: Abstract Number: 558

Major Reduction of Ultrasound Detected Synovitis during Subcutaneous Tocilizumab Treatment; Results from a Multicenter 24 Weeks Study of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 609

Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice

9:00AM-11:00AM: Abstract Number: 567

Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 619

Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 548

Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry

9:00AM-11:00AM: Abstract Number: 621

Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids

9:00AM-11:00AM: Abstract Number: 595

Predictive VALUE of CD19 SERUM Levels for LONG TERM Therapeutic Response and Utility As Biomarker for Optimization, in Rheumatoid Arthritis Patients Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 593

Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up

9:00AM-11:00AM: Abstract Number: 559

Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 598

Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study

9:00AM-11:00AM: Abstract Number: 629

Real-World Use of Tofacitinib Compared with Tumor Necrosis Factor Inhibitors in a Cohort of 211 Patients with Rheumatoid Arthritis: Data from a Drug-Based Registry Study in Taiwan

9:00AM-11:00AM: Abstract Number: 603

Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation

9:00AM-11:00AM: Abstract Number: 606

Similiar Efficacy of Tofacinitib on Disease Activity in Rheumatoid Arthritis Patients with and without Previous Biologicals; Results from the Turkbio Regıstry

9:00AM-11:00AM: Abstract Number: 623

Step-Down-Bridge Versus Tight-Step-up Therapy in Patients with Early Rheumatoid Arthritis Lacking Poor Prognostic Factors: An Economic Point of View

9:00AM-11:00AM: Abstract Number: 573

Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

9:00AM-11:00AM: Abstract Number: 616

Supplementation of Methotrexate (MTX) with Ticagrelor Therapy Suppresses Disease Activity in Patients with Moderate to Very Active Ra; Further Evidence That Adenosine and Its Receptors Mediate the Anti-Inflammatory Activity of MTX

9:00AM-11:00AM: Abstract Number: 625

Tapering of Biological Antirheumatic Drugs in Rheumatoid Arthritis Patients Is Achievable and Cost Effective in Daily Clinical Practice: DATA from the Brussels UCL RA Cohort

9:00AM-11:00AM: Abstract Number: 626

The Comparative Effectiveness of Cycling Tumor Necrosis Factor Inhibitor (TNFi) Versus Swapping to a Nontnfi on Patient-Reported Functional Ability of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 615

The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 557

The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study

9:00AM-11:00AM: Abstract Number: 585

The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia

9:00AM-11:00AM: Abstract Number: 587

The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol

9:00AM-11:00AM: Abstract Number: 555

Three Year Outcomes of Patients with Elderly-Onset Rheumatoid Arthritis Treated with a Therapeutic Strategy Targeting Low Disease Activity, and Impact of Adverse Events on Physical Function

9:00AM-11:00AM: Abstract Number: 575

Time to Discontinuation of Biologic Therapy By Mechanism of Action in Rheumatoid Arthritis: Results from a Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 556

Treatment Initiation and Duration in DMARD Naïve Rheumatoid Arthritis Patients: Analysis of US Health Plan Claims

9:00AM-11:00AM: Abstract Number: 561

U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination

9:00AM-11:00AM: Abstract Number: 571

United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab

9:00AM-11:00AM: Abstract Number: 549

Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].